Wintermute Biomedical participated in BIO-Europe 2025, connecting with pharmaceutical, biotechnology and investment leaders to advance international partnering opportunities for Solexan.
Wintermute Biomedical participated in BIO-Europe 2025 in Vienna, Austria, joining biotechnology, pharmaceutical and investment leaders from around the world at one of Europe’s premier life sciences partnering events.
BIO-Europe brings together biotechnology companies, pharmaceutical organisations, investors and business development leaders to establish new partnerships, explore licensing opportunities and progress innovative therapeutics through development and towards patients.
Wintermute’s participation at BIO-Europe provided an important opportunity to continue building international awareness of Solexan™, our investigational topical antiviral being developed for the treatment of herpes zoster (shingles).
Over three days in Vienna, the Wintermute team participated in a programme of partnering and business development meetings with organisations across the global pharmaceutical, biotechnology and investment sectors.
These discussions provided an opportunity to present the Solexan™ development programme, explore potential strategic collaborations and identify organisations whose capabilities could support the programme through its next stages of clinical development and future commercialisation.
Europe represents an important component of Wintermute Biomedical’s global business development strategy.
Participation at BIO-Europe enabled Wintermute to strengthen existing relationships while establishing new connections across the European pharmaceutical and biotechnology ecosystem.
The conference also provided valuable insight into current partnering priorities, investment trends and the evolving development landscape for innovative therapeutics.
Wintermute looks forward to continuing the relationships and discussions established in Vienna as we work to advance Solexan™ and develop a new treatment option for people affected by shingles.